Evidence map›Paper›PMID 32603404›Full record

ArticleCarcinogenesis2020

Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.

Shanshan Deng, Marco Ramos-Castaneda, Walter V Velasco, Michael J Clowers, Berenice A Gutierrez, Oscar Noble, Yiping Dong, Melody Zarghooni, Lucero Alvarado, Mauricio S Caetano and 8 more

Open access · greenAbstract read
In one paragraph

Article in Carcinogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Pulmonary Inflammation and KRAS Mutation in Lung Cancer.Advances in experimental medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Shanshan DengDepartment of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Marco Ramos-CastanedaDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Walter V VelascoDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J ClowersDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Berenice A GutierrezDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oscar NobleDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yiping DongDepartment of Oncology Radiotherapy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Melody ZarghooniDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lucero AlvaradoDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mauricio S CaetanoDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shuanying YangDepartment of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Edwin J OstrinDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carmen BehrensDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laura P StabileDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Humam KadaraThe University of Texas M.D. Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Stephanie S WatowichThe University of Texas M.D. Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Seyed Javad MoghaddamDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USFirst Affiliated Hospital of Xi'an Jiaotong University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNUPMC Hillman Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signalingR01CA225977 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MOGHADDAM, SEYED JAVAD MIRHASSANI · 2018 to 2022
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA225977
6 · The paper itself

Abstract

K-ras mutant lung adenocarcinoma (LUAD) is the most common type of lung cancer, displays abysmal prognosis and is tightly linked to tumor-promoting inflammation, which is increasingly recognized as a target for therapeutic intervention. We have recently shown a gender-specific role for epithelial Stat3 signaling in the pathogenesis of K-ras mutant LUAD. The absence of epithelial Stat3 in male K-ras mutant mice (LR/Stat3Δ/Δ mice) promoted tumorigenesis and induced a nuclear factor-kappaB (NF-κB)-driven pro-tumor immune response while reducing tumorigenesis and enhancing anti-tumor immunity in female counterparts. In the present study, we manipulated estrogen and NF-κB signaling to study the mechanisms underlying this intriguing gender-disparity. In LR/Stat3Δ/Δ females, estrogen deprivation by bilateral oophorectomy resulted in higher tumor burden, an induction of NF-κB-driven immunosuppressive response, and reduced anti-tumor cytotoxicity, whereas estrogen replacement reversed these changes. On the other hand, exogenous estrogen in males successfully inhibited tumorigenesis, attenuated NF-κB-driven immunosuppression and boosted anti-tumor immunity. Mechanistically, genetic targeting of epithelial NF-κB activity resulted in reduced tumorigenesis and enhanced the anti-tumor immune response in LR/Stat3Δ/Δ males, but not females. Our data suggest that estrogen exerts a context-specific anti-tumor effect through inhibiting NF-κB-driven tumor-promoting inflammation and provide insights into developing novel personalized therapeutic strategies for K-ras mutant LUAD.

Indexed as

ImmunomodulationAdenocarcinoma of LungAnimalsCell Transformation, NeoplasticEstrogensFemaleHumansImmunityLung NeoplasmsMaleMiceMutationNF-kappa BProto-Oncogene Proteins p21(ras)STAT3 Transcription FactorTumor Cells, CulturedEstrogensKRAS protein, humanNF-kappa BProto-Oncogene Proteins p21(ras)STAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID32603404
PMCPMC7896112
OpenAlexW3039484325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.